This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D81.0 | Synonyms: reticular dysgenesis, Reticular dysgenesis, De Vaal disease, SCID-RD, AK2 deficiency severe combined immunodeficiency
Reticular dysgenesis was first described in 1959 by the Dutch pediatricians De Vaal and Seynhaeve in twin boys who died within the first few days of life. Both infants died of severe bacterial infections within days of birth, and autopsy showed extreme hypoplasia of the lymph nodes, thymus, and spleen and complete absence of granulocytic cells. The disease is also called 'De Vaal disease' after its discoverer.
Over the following decades, as sporadic cases were reported, it was classified as the most severe form of SCID, characterized by defects in the development of both lymphocytes and myeloid cells (especially the granulocytic lineage). In the 1990s–2000s, as hematopoietic stem cell transplantation (HSCT) became established as the main treatment, cases of survival began to be reported.
In 2009, Lagresle-Peyrou et al. and Pannicke et al. independently showed that mutations in the gene for adenylate kinase 2 (AK2), located in the mitochondrial intermembrane space, cause reticular dysgenesis. This discovery greatly expanded the understanding of the energy metabolism dependence of common myeloid-lymphoid progenitor cells and of the mechanisms of hematopoietic development.
In Korea, reports of reticular dysgenesis are very rare, and a small number of cases have been recorded through the national rare immunodeficiency registry program. Early diagnostic capability is improving with the introduction of newborn immunodeficiency screening (TREC/KREC-based).
The cause of reticular dysgenesis is loss-of-function mutations in the AK2 (Adenylate Kinase 2) gene. AK2 is an enzyme present in the mitochondrial intermembrane space that catalyzes the reaction AMP + ATP ↔ 2ADP and is involved in cellular energy homeostasis and regulation of apoptosis.
Loss of AK2 function disrupts mitochondrial energy balance, inducing cell death in early hematopoietic progenitor cells. This affects both myeloid (granulocytic lineage) and lymphoid progenitor cells, but the block in development of the granulocytic lineage is particularly pronounced.
AK2 protein is also highly expressed in the stria vascularis of the inner ear, and sensorineural hearing loss has been reported to accompany the disease in some patients.
Reticular dysgenesis follows an autosomal recessive mode of inheritance. The AK2 gene is located on the long arm of chromosome 1 (1p34.1), and heterozygous carriers show a normal phenotype.
The pathogenic AK2 variants reported to date are diverse, including nonsense mutations, frameshift insertions/deletions, splice-site variants, and missense variants. Most variants result in complete loss of protein function.
There are reports that a less severe phenotype may occur with missense variants that retain some residual AK2 enzyme activity, but most patients show extreme granulocyte deficiency and lymphocyte deficiency.
Reticular dysgenesis is the rarest type of SCID, estimated to account for about 1–2% of all SCID. Around 100 or fewer cases have been reported in the literature worldwide, and incidence is relatively higher in populations with a high frequency of consanguineous marriage.
The overall incidence of SCID is estimated at about 1 per 50,000–100,000 newborns, and reticular dysgenesis accounts for an extremely small fraction of these. With the spread of newborn screening (TREC-based), the actual frequency of occurrence is being determined more accurately than in the past.
The exact prevalence of reticular dysgenesis in Korea is unknown. Cases registered under code D81.0 with the rare disease information center of the Korea Disease Control and Prevention Agency (KDCA) are extremely few. Establishment of a multicenter rare immunodeficiency registry and expansion of newborn screening programs are in progress.
AK2 catalyzes reversible phosphate group transfer between ATP and AMP in the mitochondrial intermembrane space. In AK2 deficiency, the energy balance of the mitochondrial intermembrane space is disrupted, inducing excessive production of reactive oxygen species (ROS) and loss of mitochondrial membrane potential. This activates the intrinsic apoptosis pathway (mitochondrial pathway), causing massive cell death of early hematopoietic progenitor cells (common myeloid-lymphoid progenitors, CLP, GMP).
The effect of AK2 deficiency is particularly marked at the granulocyte-monocyte progenitor (GMP) stage. Development of the granulocytic lineage, including neutrophils, is almost completely blocked, resulting in severe agranulocytosis.
The CLP (common lymphoid progenitor), the common progenitor of T cells and B cells, is also affected by AK2 deficiency, causing marked reductions in T, B, and NK cells. This results in SCID with the typical T-B-NK- phenotype.
Reticular dysgenesis presents in the neonatal period or within the first few weeks of life with extreme susceptibility to infection. Bacterial infections due to granulocyte deficiency can occur even early in life, before maternal antibodies (IgG) are depleted. Fever, respiratory distress, skin infections, and sepsis appear as early symptoms.
Severe infections with various pathogens recur, including bacteria (Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, etc.), fungi (Candida, Aspergillus), viruses (CMV, RSV, adenovirus), and protozoa (Pneumocystis jirovecii). After 3–6 months of age, with the depletion of maternal antibodies, the frequency and severity of infections increase sharply.
Some patients have accompanying sensorineural hearing loss due to impaired expression of AK2 protein in the inner ear. The hearing loss is bilateral, and early detection is important.
On physical examination, marked hypoplasia or absence of the thymus and lymph nodes and splenic hypoplasia are characteristic. Underdeveloped tonsils, nonpalpable lymph nodes, and absence of the thymic shadow on chest radiography are representative findings.
In peripheral blood, the complete blood count (CBC) characteristically shows severe granulocyte deficiency (absolute neutrophil count <200/μL or complete absence) and lymphopenia (absolute lymphocyte count <300/μL). The platelet and erythroid lineages are generally normal.
Flow cytometry confirms a T-B-NK- phenotype, with marked reduction or absence of T cells (CD3+), B cells (CD19+), and NK cells (CD16+/CD56+). Serum immunoglobulins (IgG, IgA, IgM) may appear normal early because of maternal antibodies but then decrease sharply.
For newborn screening for SCID, quantification of T-cell receptor excision circles (TREC) from dried blood spots is used as the standard method. In reticular dysgenesis, TREC levels are extremely low or undetectable because of T-cell deficiency. The United States has performed TREC-based newborn screening since 2010, and many European countries since 2014.
In Korea, TREC/KREC-based newborn immunodeficiency screening is being performed on a pilot basis at some institutions, and discussions on nationwide introduction are under way.
When a sibling has been diagnosed with reticular dysgenesis or SCID, immediate CBC, lymphocyte subset testing, and genetic testing should be performed in subsequently born siblings.
Complete blood count (CBC) confirms severe granulocyte deficiency and lymphopenia. Flow cytometry measures T (CD3+), B (CD19+), and NK (CD16+/CD56+) cell counts and confirms the T-B-NK- phenotype. Measurement of serum immunoglobulin concentrations (IgG, IgA, IgM).
Pathogenic variants are confirmed by AK2 gene panel testing or whole exome sequencing (WES). Prenatal genetic diagnosis is available; when there is a family history, AK2 gene analysis is performed after chorionic villus sampling or amniocentesis at 10–12 weeks of gestation.
Bone marrow biopsy confirms marked reduction or absence of granulocytic and lymphoid cells, with relative preservation of the erythroid and megakaryocytic lineages. This is a characteristic finding of reticular dysgenesis.
Currently, the only curative treatment for reticular dysgenesis is hematopoietic stem cell transplantation (HSCT). Transplantation as early as possible, before infections occur, is closely related to prognosis. An HLA-matched sibling donor is ideal, but when this is not possible, matched unrelated donor or parental haploidentical transplantation is also performed.
To prevent infection before HSCT, protective isolation, intravenous immunoglobulin (IVIG) administration, and antibacterial·antifungal·antiviral prophylaxis are implemented. Live vaccination is absolutely contraindicated, and CMV-negative irradiated blood products are used.
G-CSF administration can induce a transient increase in neutrophils in some patients but is not a fundamental treatment and is used as bridging therapy before HSCT.
Gene therapy research targeting AK2 gene deficiency is at the preclinical stage and has not yet reached clinical application.
Without HSCT, reticular dysgenesis is a fatal disease in which patients die of overwhelming infection within weeks to months of birth. In the past, when there was no basis for diagnosis and treatment, most patients died within the first year of life.
Long-term survival is possible with early HSCT. In multicenter data published since the 2010s, survival improved significantly with early transplantation (performed before infection). The completeness of immune reconstitution after transplantation, the degree of donor-recipient HLA matching, and the infection status before transplantation are decisive for prognosis.
In patients surviving after HSCT, abnormalities in immune reconstitution, graft-versus-host disease (GvHD), sensorineural hearing loss, and growth and developmental problems are issues for long-term follow-up.
Early introduction of TREC-based newborn screening enables diagnosis and treatment before infections occur, greatly improving prognosis. In newborns with positive screening results, prompt confirmatory testing and referral to a specialized immunodeficiency center are essential.
Because the mode of inheritance is autosomal recessive, both parents of an affected child are AK2 carriers. In subsequent pregnancies, affected fetuses can be identified early through prenatal genetic diagnosis (CVS or amniocentesis).
After diagnosis and until HSCT, protective isolation, no live vaccines, regular IVIG administration, Pneumocystis jirovecii prophylaxis (trimethoprim/sulfamethoxazole), and CMV prophylaxis are strictly implemented.